News Release

The Marketing of Cervical Cancer Drug


The New York Times reports today in an extensive article titled “Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise” that “the lightning-fast transition from newly minted vaccine to must-have injection in the United States and Europe represents a triumph of what the manufacturers call education and their critics call marketing. The vaccines, which offer some protection against infection from sexually transmitted viruses, are far more expensive than earlier vaccines against other diseases…”

Co-founder of the D.C. Health Care Coalition and a member of the Parents and Citizens Committee to Stop Medical Experimentation, Dixon said today: “This drug is totally undertested and its extensive use is out of step with other widespread vaccines that have been tested over a prolonged period of time. There’s no cervical cancer epidemic in the U.S. that would justify the rush to adopt this drug. Instead of extensive testing, there’s been a massive marketing effort by Merck. Here in Washington, D.C., the city council passed legislation to mandate the widespread use of the drug on elementary school girls notwithstanding evidence from the scientific community about possible dangers.”
More Information

For more information, contact at the Institute for Public Accuracy:
Sam Husseini, (202) 347-0020; or David Zupan, (541) 484-9167